BioSurplus
Leading provider of pre-owned laboratory instruments and equipment management services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$2.4m | Series A | ||
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
BioSurplus operates in the niche market of laboratory equipment auctions, catering primarily to research institutions, biotech companies, and laboratories. The business model revolves around online auctions, where clients can bid on a wide range of scientific instruments and lab equipment. The platform utilizes a proxy bidding system similar to eBay, allowing users to place bids without constant monitoring. Revenue is generated through auction sales, with items often having reserve prices to ensure minimum sale values. The company provides a diverse inventory, including PCR systems, microscopes, and centrifuges, appealing to a specialized clientele seeking cost-effective solutions for their equipment needs. Key features include online showrooms and extended bidding times to enhance user experience.
Keywords: laboratory, equipment, auctions, proxy bidding, reserve pricing, research, biotech, online platform, scientific instruments, cost-effective.